Dr. Cathrin Rohleder, PhD
Research Fellow

Scientific interests:
Neurobiology and behavioral biology, Molecular Imaging,
Behavioral pharmacology, physiologal and morphological effects of antipsychotics



Academic education:
1999-2006 Diploma program Biology, RWTH Aachen (Diploma thesis: Investigation of auditory post-effects in screech owl (Tyto alba)).
2006-2012 Postgraduate student, University of Cologne - RG Experimental and clinical Neuropsychopharmacology in cooperation with Max-Planck-Institut for neurological research.

Dissertation:
2012 "Investigation of behavioral pharmacology and brain metabolism during acut and chronic modulation of the endocannabinoid system in rats.", University of Cologne, Faculty of Mathematics and Natural Sciences
 
Professional activity:
2006-2009 Postgraduate student, Dept. of Psychiatry and Psychotherapy, University of Cologne, Cologne, Germany
2009-2012 Postgraduate student, Central Institute of Mental Health, Mannheim, Germany
2012-2018 Post doc, Central Institute of Mental Health, Mannheim, Germany
2018-2020 Research Administration Manager and Research Fellow, Brain and Mind Centre, The University of Sydney, Sydney, Australia
 
Publications:

• A. Moldavski, H. Wenz, B. Lange, C. Rohleder, F. M. Leweke. Case Report: Severe adolescent major depressive syndrome turns out to be an unusual case of Anti-NMDA receptor encephalitis. Front Psychiatry 2021, in press.
• 0F. M. Leweke, C. Rohleder, C. W. Gerth, M. Hellmich, R. Pukrop, D. Koethe: Cannabidiol and amisulpride improve cognition in acute schizophrenia in an explorative, double-blind, active-controlled randomized clinical trial. (2021) Front Pharmacol 12:614811.
• C. G. Bien, C. Rohleder, J. E. Mueller, C. I. Bien, D. Koethe, F. M. Leweke: Neural autoantibodies in cerebrospinal fluid and serum in clinical high risk for psychosis, first-episode psychosis, and healthy volunteers. (2021) Front Psychiatry 12:654602.
• D. C. Schroeder, E. Popp, C. Rohleder, S. Vus, D. P. Bethencourt, S. R. Finke, Positron Emission Tomography Imaging of Long-Term Expression of the 18 kDa Translocator Protein After Sudden Cardiac Arrest in Rats. (2021) Shock 55(5):620-629
• A. M. Tickell, C. Rohleder, Y. J. C. Song, J. S. Carpenter, K. Harel, L. Parker, I. B. Hickie, E. Scott: Protocol for a sound adult mental health (Uspace) cohort: personalising multidimensional care in young people admitted to hospital. (2021) BMJ Open 11:e038787
• T. Woelfl, C. Rohleder, J. K. Mueller, B. Lange, A. Reuter, A. M. Schmidt, D. Koethe, M. Hellmich, F. M. Leweke: Effects of cannabidiol and delta-9-tetrahydrocannabinol on emotion, cognition and attention: A double-blind, placebo-controlled, randomized experimental trial in healthy volunteers. Front Psychiatry (2020) 11:576877
• C. Rohleder, Y. J. C. Song, J. J. Crouse, T. A. Davenport, F. Iorfino, B. Hamilton, N. Zmicerevska, A. Nichles, J. S. Carpenter, A. M. Tickell, C. Wilson, S. P. Cross, A. J. Guastella, D. Koethe, F. M. Leweke, E. M. Scott, I. B. Hickie (2020) Youth Mental Health Tracker: protocol to establish a longitudinal cohort and research database for young people attending Australian mental health services. BMJ Open 10:e035379

• D. Schroeder, E. Popp, C. Rohleder, S. Vus, D. de la Puente Bethencourt, S.-R. Finke, B. Zlatopolskiy, J. Zischler, A. Drzezga, H. Herff, T. Annecke, T. Hucho, B. Neumaier, B. W. Böttiger, H. Endepols (2020) Positron-Emission-Tomography imaging of long-term expression of the 18kDa translocator protein after sudden cardiac arrest in rats. Shock, online ahead of print, doi: 10.1097/SHK.0000000000001546.
• V. L. Chadwick, C. Rohleder, D. Koethe, F. M. Leweke (2020) Cannabinoids and the endocannabinoid system in anxiety, depression, and dysregulation of emotion in humans. Current Opinion in Psychiatry 33:20-42
• Y. Bouter, M. M. Brzózka, R. Rygula, F. M. Leweke, U. Havemann-Reinecke*, C. Rohleder* (2019) Chronic psychosocial stress causes increased anxiety-like behavior and alters endocannabinoid levels in the brain in C57Bl/6J mice. Cannabis Cannabinoid Res 5:51-61
• F. Iorfino, J. S. Carpenter, S. P. Cross, T. A. Davenport, D. F. Hermens, A. J. Guastella, C. Rohleder, J. J. Crouse, F. M. Leweke, D. Koethe, S. L. Naismith, E. M. Scott, I. B. Hickie (2019) Multidimensional outcomes in youth mental health care: what matters and why? Med J Australia 211S9:S4-S11
• J. S. Carpenter, F. Iorfino, S. P. Cross, T. A. Davenport, D. F. Hermens, C. Rohleder, J. J. Crouse, F. M. Leweke, D. Koethe, A. J. Guastella, S. L. Naismith, J. Scott, E. M. Scott, I. B. Hickie (2019) Clinical staging pathophysiological mechanisms and illness trajectories in young people with emerging mental illness. Med J Australia 211S9:S12-S22
• J. J. Crouse, C. Rohleder, J. S. Carpenter, F. Iorfino, A. M. Tickell, S. P. Cross, T. A. Davenport, D. F. Hermens, A. J. Guastella, F. M. Leweke, D. Koethe, S. L. Naismith, E. M. Scott, I. B. Hickie (2019) Comprehensive assessment in young people: Guiding measurement-based care with multidimensional and objective assessments. Med J Australia 211S9:S23-S31
• C. Rohleder, J. J. Crouse, J. S. Carpenter, F. Iorfino, S. P. Cross, T. A. Davenport, D. F. Hermens, A. J. Guastella, F. M. Leweke, D. Koethe, S. L. Naismith, E. M. Scott, I. B. Hickie (2019) Personalising care options in youth mental health: using multidimensional assessment, clinical stage, pathophysiological mechanisms, and individual illness trajectories to guide treatment selection. Med J Australia 211S9: S32-S41

• C. Rohleder, F. Pahlisch, R. Graf, H. Endepols, F. M. Leweke (2019) Differential pharmaceutical preparations of ∆9-tetrahydrocannabinol differentially affect its behavioral effects in rats. Addict Biol ePub ahead

• D. Koethe*, F. Pahlisch*, M. Hellmich*, C. Rohleder, C. Hoyer, A. Meyer-Lindenberg, E. F. Torrey, D. Piomelli, F. M. Leweke (2019) Familial abnormalities of endocannabinoid signalling in schizophrenia. World J Biol Psychiatry 20:117-125

• F. M. Leweke*, J. K. Mueller*, B. Lange, S. Fritze, C. E. Topor, D. Koethe, C. Rohleder (2018) Role of the endocannabinoid system in the pathophysiology of schizophrenia: Implications for pharmacological interventions. CNS Drugs 32:605-619

• O. Grimm, M. Löffler, S. Camping, C. Rohleder, F. M. Leweke, H. Flor (2018) Probing the endocannabinoid system in healthy volunteers: cannabidiol alters fronto-striatal resting-state connectivity. Eur Neuropsychopharmacol 28:841-849
• F. M. Leweke, C. Rohleder, J. K. Mueller, D. Hirjak, A. Meyer-Lindenberg (2018) Cannabidiol zur Verbesserung der Genesung in frühen Stadien einer Schizophrenie. Eine randomisierte, kontrollierte klinische Prüfung der adjuvanten Gabe zur individuellen antipsychotischen Behandlung. Nervenheilkunde 37:1-4
• C. Rohleder*, D. Koethe*, S. Fritze, C. E. Topor, F. M. Leweke, D. Hirjak (2018) Neural correlates of binocular depth inversion illusion in antipsychotic-naïve first-episode schizophrenia patients. Eur Arch Psychiatry Clin Neurosci DOI 10.1007/s00406-018-0886-2
• A. R. Reuter*, J. M. Bumb*, J. K. Mueller*, C. Rohleder, F. Pahlisch, F. Hanke, E. Arens, F. M. Leweke, D. Koethe#, E. Schwarz# (2017) Association of anandamide with altered binocular depth inversion illusion in schizophrenia. World J Biol Psychiatry 18:483-48
• C. Rohleder, D. Wiedermann, B. Neumaier, A. Drzezga, L. Timmermann, R. Graf, F. M. Leweke, Heike Endepols (2016) The functional networks of prepulse inhibition: Neuronal connectivity analysis based on FDG-PET in awake and unrestrained rats. Front Behav Neurosci, 7:422
• F. M. Leweke, J. K. Mueller, B. Lange, C. Rohleder (2016) Therapeutic potential of cannabinoids in psychosis. Biol Psychiatry 79:604-612
• J. K. Mueller, C. Rohleder, F. M. Leweke (2016) What is the promise of nicotinergic compounds in schizophrenia treatment? Future Med Chem 8:2009-201
• E. G. Severance, K. L. Gressitt, A. Alaedini, C. Rohleder, F. Enning, J. M. Bumb, J. K. Mueller, E. Schwarz, R. H. Yolken, F. M. Leweke (2015) IgG dynamics of dietary antigens point to cerebrospinal fluid barrier or flow dysfunction in first-episode schizophrenia. Brain Behav Immun 44, 148-58.
• M. Grosshans, E. Schwarz, J. M. Bumb, C. Schaefer, C. Rohleder, C. Vollmert, S. Vollstadt-Klein, H. Tost, A. Meyer-Lindenberg, F. Kiefer, F. M. Leweke (2014) Oleoylethanolamide and human neural responses to food stimuli in obesity. JAMA Psychiatry 71, 1254-61.
• C. Rohleder, F. Jung, H. Mertgens, D. Wiedermann, M. Sue, B. Neumaier, R. Graf, F. M. Leweke, H. Endepols (2014) Neural correlates of sensorimotor gating: a metabolic positron emission tomography study in awake rats. Front Behav Neurosci 8, 178.
• C. Schaefer, F. Enning, J. K. Mueller, J. M. Bumb, C. Rohleder, T. M. Odorfer, J. Klosterkotter, M. Hellmich, D. Koethe, C. Schmahl, M. Bohus, F. M. Leweke (2014) Fatty acid ethanolamide levels are altered in borderline personality and complex posttraumatic stress disorders. Eur Arch Psychiatry Clin Neurosci 264:459-463.
• European Network of National Networks studying Gene-Environment Interactions in, J. van Os, B. P. Rutten, I. Myin-Germeys, P. Delespaul, W. Viechtbauer, C. van Zelst, R. Bruggeman, U. Reininghaus, C. Morgan, R. M. Murray, M. Di Forti, P. McGuire, L. R. Valmaggia, M. J. Kempton, C. Gayer-Anderson, K. Hubbard, S. Beards, S. A. Stilo, A. Onyejiaka, F. Bourque, G. Modinos, S. Tognin, M. Calem, M. C. O'Donovan, M. J. Owen, P. Holmans, N. Williams, N. Craddock, A. Richards, I. Humphreys, A. Meyer-Lindenberg, F. M. Leweke, H. Tost, C. Akdeniz, C. Rohleder, J. M. Bumb, E. Schwarz et al. (2014) Identifying gene-environment interactions in schizophrenia: contemporary challenges for integrated, large-scale investigations. Schizophr Bull 40, 729-36.
• L. N. Hayes, E. G. Severance, J. T. Leek, K. L. Gressitt, C. Rohleder, J. M. Coughlin, F. M. Leweke, R. H. Yolken, A. Sawa (2014) Inflammatory molecular signature associated with infectious agents in psychosis. Schizophr Bull 40, 963-72.